News
UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
- By IPP Bureau
| February 25, 2026
The UK has given the green light to brensocatib (Brinsupri), marking the first medicine specifically licensed to treat non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the drug is approved for patients who have experienced two or more flare-ups or worsening symptoms in the past 12 months. NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production, most commonly affecting older adults.
Brensocatib works by targeting a protein called dipeptidyl peptidase 1 (DPP1), which drives lung inflammation. By blocking DPP1, the drug can help prevent flare-ups and may improve some symptoms of the disease.
“This is the first medicine licensed in the UK that specifically treats patients living with non-cystic fibrosis bronchiectasis,” said Julian Beach, MHRA Executive Director, Healthcare Quality and Access.
He added, “As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.”
The drug is available as a once-daily oral tablet. Common side effects include nose and throat infections, diarrhoea, vomiting, headache, gum problems, skin thickening, rashes, dermatitis, and hair loss.
